UA82980C2 - Замещенные амиды бензойной кислоты и их применение для угнетения ангиогенеза - Google Patents

Замещенные амиды бензойной кислоты и их применение для угнетения ангиогенеза

Info

Publication number
UA82980C2
UA82980C2 UA2002119346A UA2002119346A UA82980C2 UA 82980 C2 UA82980 C2 UA 82980C2 UA 2002119346 A UA2002119346 A UA 2002119346A UA 2002119346 A UA2002119346 A UA 2002119346A UA 82980 C2 UA82980 C2 UA 82980C2
Authority
UA
Ukraine
Prior art keywords
benzoic acid
acid amides
angiogenesis
inhibition
substituted benzoic
Prior art date
Application number
UA2002119346A
Other languages
English (en)
Ukrainian (uk)
Inventor
Андреас Гут
Дитер Сайдельманн
Original Assignee
Шеринг Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Шеринг Акциенгезельшафт filed Critical Шеринг Акциенгезельшафт
Publication of UA82980C2 publication Critical patent/UA82980C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56Amides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

В заявке описываются замещенные амиды бензойной кислоты формулы (І)Ии их применение в качестве лекарственных средств для лечения заболеваний, обусловленных стойким ангиогенезом, а также промежуточные продукты для получения указанных амидов бензойной кислоты.
UA2002119346A 2000-04-25 2001-04-24 Замещенные амиды бензойной кислоты и их применение для угнетения ангиогенеза UA82980C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10021246A DE10021246A1 (de) 2000-04-25 2000-04-25 Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
UA82980C2 true UA82980C2 (ru) 2008-06-10

Family

ID=7640467

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2002119346A UA82980C2 (ru) 2000-04-25 2001-04-24 Замещенные амиды бензойной кислоты и их применение для угнетения ангиогенеза

Country Status (27)

Country Link
US (1) US20110009447A1 (ru)
EP (1) EP1280776B1 (ru)
JP (1) JP2004512259A (ru)
KR (1) KR100904101B1 (ru)
CN (1) CN1285578C (ru)
AT (1) ATE446288T1 (ru)
AU (2) AU5227201A (ru)
BG (1) BG107212A (ru)
BR (1) BR0110246A (ru)
CA (1) CA2406392C (ru)
CZ (1) CZ20023545A3 (ru)
DE (2) DE10021246A1 (ru)
EE (1) EE200200609A (ru)
ES (1) ES2334433T3 (ru)
HR (1) HRP20020933A2 (ru)
HU (1) HUP0300920A1 (ru)
IL (1) IL152292A0 (ru)
MX (1) MXPA02010559A (ru)
NO (1) NO325445B1 (ru)
NZ (1) NZ521681A (ru)
PL (1) PL358457A1 (ru)
RU (1) RU2353618C2 (ru)
SK (1) SK15222002A3 (ru)
UA (1) UA82980C2 (ru)
WO (1) WO2001081311A1 (ru)
YU (1) YU71102A (ru)
ZA (1) ZA200209494B (ru)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US20030134836A1 (en) 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
US7307088B2 (en) 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
JP2007512227A (ja) 2003-08-06 2007-05-17 セノミックス、インコーポレイテッド T1rヘテロオリゴマー味覚受容体、この受容体を発現する細胞株、および味覚化合物
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
TW200529812A (en) * 2003-12-26 2005-09-16 Chugai Pharmaceutical Co Ltd Benzamide derivatives
DE102004009238A1 (de) * 2004-02-26 2005-09-08 Merck Patent Gmbh Arylamid-Derivate
US8247556B2 (en) 2005-10-21 2012-08-21 Amgen Inc. Method for preparing 6-substituted-7-aza-indoles
DK1973545T3 (da) 2005-12-23 2013-02-25 Ariad Pharma Inc Bicykliske heteroarylforbindelser
EP3235811B1 (en) 2006-04-21 2018-07-25 Senomyx, Inc. Process of preparing oxalamides
CA2651072A1 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
WO2007133560A2 (en) * 2006-05-08 2007-11-22 Ariad Pharmaceuticals, Inc. Acetylenic heteroaryl compounds
ES2555515T3 (es) 2006-05-08 2016-01-04 Ariad Pharmaceuticals, Inc. Compuestos de heteroarilo monocíclico
BRPI0718895A2 (pt) * 2006-11-16 2013-12-10 Allergan Inc Composto de sulfoximina e uso do referido composto
EP2923703B1 (en) 2006-12-15 2018-09-19 NantBio, Inc. Triazine derivatives and their therapeutical applications
WO2008131368A2 (en) 2007-04-20 2008-10-30 Acucela Inc. Styrenyl derivative compounds for treating ophthalmic diseases and disorders
TWI490214B (zh) * 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為vap-1抑制劑之用途
US8350026B2 (en) 2008-08-27 2013-01-08 Leo Pharma A/S VEGF-2 receptor and protein tyrosine kinase inhibitors and pharmaceutical use thereof
CA2743449C (en) 2008-11-12 2016-10-18 Ariad Pharmaceuticals, Inc. Pyrazinopyrazines and derivatives as kinase inhibitors
JP2012513464A (ja) 2008-12-23 2012-06-14 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク ホスホジエステラーゼ阻害剤及びその使用
CA2765030C (en) 2009-06-09 2015-10-27 California Capital Equity, Llc Triazine derivatives and their therapeutical applications
CN102573484B (zh) 2009-06-09 2015-07-01 加利福尼亚资本权益有限责任公司 苄基取代的三嗪衍生物及其治疗应用
TW201103904A (en) * 2009-06-11 2011-02-01 Hoffmann La Roche Janus kinase inhibitor compounds and methods
TW201307292A (zh) 2010-12-17 2013-02-16 Hoffmann La Roche 經取代之6,6-稠合含氮雜環化合物及其用途
CA2815506C (en) 2012-12-12 2018-12-11 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
MX2016006325A (es) * 2013-11-15 2016-12-02 Wistar Inst Inhibidores del antígeno nuclear 1 de epstein-barr, y su método de uso.
EP3294705B1 (en) 2015-05-14 2021-07-21 The Wistar Institute Of Anatomy And Biology Ebna1 inhibitors and methods using same
CN106740403A (zh) * 2017-03-21 2017-05-31 西北工业大学 一种液氮动力输出系统及混合动力冷链运输车
WO2019222470A1 (en) 2018-05-17 2019-11-21 The Wistar Institute Ebna1 inhibitor crystalline forms, and methods of preparing and using same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1643265C3 (de) * 1967-12-22 1978-08-31 C.H. Boehringer Sohn, 6507 Ingelheim Kernsubstituierte 2-Aminomethylbenzhydrole, Verfahren zu deren Herstellung und Arzneimittel auf der Basis dieser Verbindungen
JPH02218654A (ja) * 1988-10-12 1990-08-31 Ono Pharmaceut Co Ltd 安息香酸誘導体、それらの製造方法およびそれらを含有する薬剤
DE19648793A1 (de) * 1996-11-26 1998-05-28 Basf Ag Neue Benzamide und deren Anwendung
US5863455A (en) * 1997-07-14 1999-01-26 Abb Power T&D Company Inc. Colloidal insulating and cooling fluid
JP3013989B2 (ja) * 1998-03-26 2000-02-28 日本たばこ産業株式会社 アミド誘導体及びノシセプチンアンタゴニスト
CA2336848A1 (en) * 1998-07-10 2000-01-20 Merck & Co., Inc. Novel angiogenesis inhibitors
EP1109555A4 (en) * 1998-08-31 2001-11-21 Merck & Co Inc Novel angiogenesis inhibitors
CN1342077A (zh) * 1998-11-06 2002-03-27 诺尔股份公司 抑制血管渗透性过高的形成
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
HN2001000008A (es) * 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo

Also Published As

Publication number Publication date
SK15222002A3 (sk) 2003-06-03
IL152292A0 (en) 2003-05-29
CZ20023545A3 (cs) 2003-02-12
CN1285578C (zh) 2006-11-22
NZ521681A (en) 2006-03-31
EP1280776A1 (de) 2003-02-05
HRP20020933A2 (en) 2005-02-28
ES2334433T3 (es) 2010-03-10
CN1426396A (zh) 2003-06-25
NO20025102D0 (no) 2002-10-24
DE50115189D1 (de) 2009-12-03
CA2406392A1 (en) 2001-11-01
EP1280776B1 (de) 2009-10-21
MXPA02010559A (es) 2003-03-10
CA2406392C (en) 2011-08-30
AU2001252272B2 (en) 2007-03-29
NO325445B1 (no) 2008-05-05
BG107212A (bg) 2003-05-30
YU71102A (sh) 2006-03-03
HK1056559A1 (en) 2004-02-20
WO2001081311A1 (de) 2001-11-01
NO20025102L (no) 2002-12-17
HUP0300920A1 (hu) 2003-07-28
DE10021246A1 (de) 2001-10-31
BR0110246A (pt) 2003-03-05
US20110009447A1 (en) 2011-01-13
KR20020093946A (ko) 2002-12-16
KR100904101B1 (ko) 2009-06-24
PL358457A1 (en) 2004-08-09
ZA200209494B (en) 2004-07-14
AU5227201A (en) 2001-11-07
JP2004512259A (ja) 2004-04-22
ATE446288T1 (de) 2009-11-15
EE200200609A (et) 2004-04-15
RU2353618C2 (ru) 2009-04-27

Similar Documents

Publication Publication Date Title
YU71102A (sh) Supstituisani amidi benzoeve kiseline i njihova primena kao sredstva za lečenje
YU31801A (sh) Amidi antranilne kiseline i njihova upotreba kao leka
CA2534571A1 (en) Substituted isoquinoline derivatives and methods of use
NL300933I2 (nl) Letermovir
MXPA02007942A (es) Derivados de pirrolopirimidinona, procesos de preparacion y uso.
YU82702A (sh) Ortosupstituisani amidi antranilne kiseline i njihova primena kao sredstva za lečenje
WO2002068406A3 (en) Substituted amine derivatives and their use for the treatment of angiogenesis
AP2088A (en) Phenethanolamine derivatives for treatment of respiratory diseases
CA2434277A1 (en) Substituted alkylamine derivatives and methods of use
DE60118003D1 (de) Harnstoffderivate und ihre verwendung
BG105513A (en) Substituted benzopyran analogs for the treatment of inflammation
WO2004005279A3 (en) Substituted anthranilic amide derivatives and methods of use
WO2004007457A3 (en) Substituted benzylamine derivatives and methods of use
MXPA04002405A (es) Derivados de fenetanolamina para tratamiento de enfermedades respiratorias.
ATE365720T1 (de) Agonisten von beta-adrenorezeptoren
JO2493B1 (en) New phenyl azatidinone with improved physical properties and methods of preparation of drugs containing it and its uses
MXPA05013469A (es) Derivados de piperazina y metodos de uso.
MY128241A (en) Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
PL328225A1 (en) Diphenylstilbenes as pro-medications used to produce cox-2-inhibitors
DE60107832D1 (en) Chromenylmethylpyrimidindiamine als antibakterielle wirkstoffe
WO2001081298A3 (en) Cyclic carboxylic acids as integrin antagonists
MXPA03002047A (es) Fenilciclohexanocarboxamidas substituidas y su uso.
HUP9801925A1 (hu) Nátrium/hidrogén-csere inhibítorok alkalmazása protozoák által okozott betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
DE60209122D1 (de) Bernsteinsäurederivate
ATE265418T1 (de) Neue substituierte 3-phenoxy- und 3- phenylalkyloxy-2-phenyl-propylamine